Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 15, 2025, UBS reaffirmed its ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...